I am not receiving compensation for it. In December 2019, Intra-Cellulars first drug named CAPLYTA was approved by the FDA for the treatment of adult patients with schizophrenia. The Company submitted a Marketing Authorization Application to the. M&A deal flow dwindled in 2021, reflecting stricter antitrust laws. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. While oncology and immuno-oncology are the key areas of focus, treatments for rare diseases and gene-editing companies also promise potential, making them lucrative investment areas. Analysts, on average, see scope for about 90% upside for Mirati stock. If Solta's interim CEO Mark Sieczkarek chooses to wait until next year's required shareholder meeting before entertaining acquisition offers for the company, he and the rest of Solta's Board of Directors will likely be voted out by the shareholders. We'll see if that happens, but I think it would be one of the top megamerger acquisition candidates that are on the market right now. The company has already seven products on the market. Alexion Pharmaceuticals. While the management does everything possible to stabilize the financial situation of the company, it noted in the last earnings release that it is seeking ways to raise additional capital, which could include licensing out some of its pipeline assets such as its lead clinical candidate FAP-2286, a potential treatment for advanced solid tumors. There's some people who say that they're disappointed because a company got taken out because they'd rather own the company and profit from the growth of that company individually. We believe there is merit to the current rumors surrounding AcelRx. Sold CoTherix, Inc. to Actelion Pharmaceuticals Ltd.: Mr. Rosen served on the Board of Directors of CoTherix, Inc. Actelion Pharmaceuticals bought out CoTherix for $420M. But I think there's also a good fit on Seagen's pipeline too. 9. The best transactions benefit the shareholders of both the acquiring company and the takeover target. Then I'll throw one more out -- Vertex (VRTX 3.67%) buying CRISPR Therapeutics (CRSP 3.66%). Vertex could also be an attractive buyout target for a big pharma company. All rights reserved. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Copy and paste multiple symbols separated by spaces. (Source: EY 2019 M&A Firepower Report) 1. For this story, BioPharma Dive looked only at companies developing human medicines. We've just talked about two deals that have been announced this week. Type a symbol or company name. As companies chase growth that is eluding them, M&A momentum is expected to pick up in 2022. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Stay on top of what's happening at JPM. Brian, what are some acquisitions that you'd like to. earnings call is. Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. . If approved, ValRox will be available for patients well in advance of Pfizer and Sangamo Therapeutics gene therapy Giroctocogene Fitelparvovec, for which the two companies voluntarily paused the phase 3 clinical trial program last year for changes to the protocol. Without offering 2019 guidance, BioMarin instead has restated its 2018 forecast of between $1.47 billion and $1.53 billiona jump of between 12% and 16.5% over 2017as well as a net loss of . Use a + to require a term in results and - to exclude terms. Someone is "mistaken" here. Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business. Keep track of M&A as it happens with this database. Sold Inspire Pharmaceuticals to Merck & Co. (MRK): Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc. Merck bought out Inspire for $430M, or a 26% premium over the current share price. We have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. Price as of January 17, 2023, 4:00 p.m. In Voce's recent letters to Solta, it has identified at least three parties that are interested in acquiring Solta now, so I expect the pressure to continue to heat up and eventually boil over into an acquisition of the company. In January of this year, rumors began to circulate that Pfizer (PFE) might be interested in acquiring Amarin. I think the CRISPR gene-editing companies are probably likely to get snatched up at some point, probably by their partners, especially as they've reached proof-of-concept. Otrexyo is a registered trademark of Pfizer. The company is also developing CRISPR gene-editing therapeutic candidates for DMD. Create your Watchlist to save your favorite quotes on Nasdaq.com. You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here. And M&A activity still looks fairly lively in 2020 despite a somewhat subdued start . The speculation gained further ground when Denmark-based Novo Nordisk (NYSE:NVO) announced a deal to buy Dicerna, also a RNAi therapeutic company. AMAG Pharmaceuticals (Market Cap $0.7bn) US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women's health - specifically Novartis AG - due to the potential of bremelanotide in hypoactive sexual desire disorder (HSDD). Acquisitions are back in full swing in the sector. All rights reserved. Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a. e have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. I own Seagen. Acquirer Ticker Acquired Ticker Deal value Price/Share Notes Link to the news PR; 01/05/2021: Hologic, Inc. HOLX: Private-German co. $64M-leader in biopsy site markers: https://bwnews.pr/2L3d7lF: Since then, Alnylam has received FDA approval for several drugs and has developed a robust development pipeline. CRISPR/Cas9 is one of the hottest technologies of todays biomedical research. Other approved drugs in the companys portfolio continue to do well. Abbott Laboratories bought out Solvay Pharmaceuticals for $6.1B. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. The top ten deals in the industry totaled $97 billion in 2020, led by the $39-billion buyout of Alexion Pharmaceuticals ( ALXN) - Get Free Report late in the year by AstraZeneca ( AZN) - Get Free. Keith Speights owns shares of Vertex Pharmaceuticals. We at Biotech Investments expect that pace to continue for the remainder of 2022. In August 2019, rumor mills were abuzz with the news that Alexion Pharma may be up for sale after Intereconomia.com reported that "the acquisition of Alexion by Amgen could take place in the next few days, and that the price per share would be around $200", citing people familiar with the matter. The quest behind the drive is to fill potential gaps in the pipeline. The rumors on Obagi turned out to be correct, as the company was sold last. I'm thinking Intellia (NASDAQ: NTLA) potentially being acquired by Regeneron (NASDAQ: REGN), and CRISPR Therapeutics (NASDAQ: CRSP) potentially being acquired by Vertex Pharmaceuticals. Invest better with The Motley Fool. Sold GenPharm International, Inc. to Medarex, which was then acquired by Bristol-Myers Squibb (BMY): Mr. Rosen served as Director of Corporate Development at GenPharm International. 1125 N. Charles St, Baltimore, MD 21201. The database, which shows drugmaker acquisitions that happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Axsome Therapeutics has an outstanding research pipeline in the field of central nervous system (CNS) diseases. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. For those with multiple focuses, the chosen therapeutic area is based on lead asset or, lacking one that's distinctly identified, the company is classified under "other.". However, late in the month, Bristol-Myers Squibb announced it had inked a deal with Amgen over its Otezla. In addition, the American company has several commercial and research successes, including recent positive Phase 3 clinical trial data for its ATTR amyloidosis drug ONPATTRO (Patisiran). In fact, the second quarter hit a five-year low in both the value and number of biopharma transactions. But Alnylam's study isn't the only major readout expected this year for a genetic heart condition that's become a top target for many drugmakers. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines. If the letter of intent to acquire your company has been signed, you might be asking what happens next. Meanwhile, earlier this month, U.K.-based Elliott Advisors, one of the largest stakeholders in Alexion, urged the company to take a proactive approach and put itself up for sale to maximize the chance of an optimal outcome. Mergers and acquisition (M&A) activity in India is heating up. This submission marks the first marketing application submission for a gene therapy product for any type of hemophilia. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. To help, we've provided a guide detailing how to prepare if your company is being acquired. Antares Pharma ( ATRS ) We first began to hear acquisition rumors in Antares in late 2011. Calibre Scientific is pleased to announce the acquisition of Glass Chemicals, a Spanish distributor of scientific consumables, equipment and services for the life sciences, diagnostics, and industrial sectors. 12. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Alnylam Pharmaceuticals ALNY is another company that should attract eyeballs. Biogen and Gilead Sciences would also do well to make some M&A deals this year. Therefore, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than $10B each. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. This year has seen a modest rebound after a slow start, and analysts believe a further resurgence is likely. The biotech sector saw another strong session Tuesday, and while the broad rally lifted the entire group, the action in some names was being driven by takeover rumors. Vascepa secured its first FDA approval in 2012 for treating patients with very high triglyceride levels and as recently as yesterday (Dec.14) was approved for wider use, i.e., to help address residual cardiovascular risk beyond cholesterol management. This therapeutic has been licensed to Swiss pharma giant Novartis. At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." In the wake of generic drugs eating into the sales of off-patent branded drugs, growing pressure from regulators to reduce the prices of drugs, drying pipelines, and ever-increasing R&D costs, there has been an increasing consolidation within the drug industry. Someone is "mistaken" here. Just recently, Bayer bought out Conceptus for $1.1B. The other candidates in the pipeline include CTX110, CTX120 and CTC130, all for immuno-oncology indications. Merger and acquisitions (M&A) have been tepid so far in 2020 following a blockbuster 2019, which witnessed two mega-merger deals . Dan utilizes his experience reading and reviewing scientific literature to evaluate prospects for success. I don't know. Sold Pharsight Corporation to Tripos International: Mr. Rosen served on the Board of Directors of Pharsight Corporation. The Motley Fool has a disclosure policy. If there's anything we've missed, or any additional information you'd like to see, please reach out and let us know. Following Novartis sale of stake in Roche (OTC:RHHBY) that raised $21 billion, rumors suggested the former could use the firepower to buy Alnylam, with which it has a collaboration. Last month, Adaptimmune announced that SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) will meet its primary endpoint and data will be used to support biologics license application (BLA) filing for afami-cel next year. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Best Penny Stocks . The rumors on Obagi turned out to be correct, as the company was sold last year to Valeant (VRX) for $24 a share. In the business of drug development, deals can be just as important as scientific breakthroughs. *Average returns of all recommendations since inception. To make the world smarter, happier, and richer. Ipsen bought out Tercica for $404M, or a 104% premium over the current stock price. The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. The first few months lived up to expectations: All of the top 10 M&A deals of January-June 2018 exceeded $1.5 billion, paced by the completion of Bayer's $63 billion buyout of Monsanto . Given that the FDA is yet to approve a NASH drug, it is worth taking a risk with this one-trick pony. Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. This conference call is no longer online, but the. Brian, what are some acquisitions that you'd like to see take place in the biopharmaceutical world in 2022. *Premiums are calculated from the closing price of the acquired company's shares on the previous trading day. AcelRx (ACRX). I don't know, maybe they could out-license those. Whether M&A activity continues will have a significant effect on which startups and drug programs get funded and advanced. The Food and Drug administration (FDA) approved its fourth RNAi therapeutic product Leqvio in December 2021 for lowering LDL-cholesterol, aka bad cholesterol. Additionally, it has a robust gene therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications. 6 min read Merger and acquisitions (M&A) have been tepid so far in 2020. Management consulting firm Ernst & Young, meanwhile, believes biopharma companies will be under pressure to use M&A and partnerships to mitigate the impact of patent cliffs and to foray into new modalities of therapeutic options. Is It Too Late to Buy Vertex Pharmaceuticals Stock? The FDA decision on Pemigatinib is expected by May 30, 2020. Go and get our, Eckert & Ziegler Strahlen- und Medizintechnik AG. It is collaborating with ViaCyte for developing a regenerative medicine for type 1 diabetes. Date Acquirer Co. Invest better with The Motley Fool. Trading stocks is risky -- always be sure to know and understand your risk tolerance. Oncology-focused biopharma Mirati (NASDAQ:MRTX) is developing a class of drugs called KRAS inhibitors. Rumors. Cambridge, Massachusetts-based Crisprs lead asset CTX001 is in development for two indications beta thalassemia and sickle cell disease in collaboration with Vertex Pharma. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. The stock has lost 14% of its value since February and trades around $80. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. Later, Bristol-Myers Squibb for $2.4B. Shanthi is a contributor to InvestorPlace.com as well as a staff writer with Benzinga. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Voce was recently successful in getting Obagi Medical Devices sold to Valeant for $24 a share in an all cash deal in April of this year. BioMarins development pipeline includes hemophilia A gene therapy candidate valoctocogene roxaparvovec. They are my opinions only. Cash position at the end of the fiscal year was at $1.52 billion. Moreover, companies investing in mRNA technology are gaining a lot of attention, given the success of the technology in the development of COVID-19 vaccines. Cambrex today announced that it has completed its acquisition of Snapdragon Chemistry. Please. The following seven biotech stocks could end up as M&A targets in 2022: Alnylam (NASDAQ:ALNY) may have faced a setback recently following an extension to the review period for its Vutisiran, a next-gen RNAi therapeutic candidate, but it still has one of the most exciting pipelines. These symbols will be available throughout the site during your session. On the date of publication, Shanthi Rexaline did not have (either directly or indirectly) any positions in the securities mentioned in this article. 1125 N. Charles St, Baltimore, MD 21201. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. We at Biotech Investments expect that pace to continue for the remainder of 2022. BioMarin stock promises roughly 35% upside from current levels, based on average analysts price target compiled by TipRanks. Keith Speights: All right, Brian. I think that would potentially drive sales of Opdivo. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Sold Kos Pharmaceuticals to Abbott Laboratories: Mr. King served as Executive Vice President of Commercial Operations of Kos Pharmaceuticals, Inc. See above section for details on that buyout. Brian Orelli: I'd like to see Bristol-Myers Squibb (BMY -0.28%) acquire Seagen (SGEN -1.71%). In this year's M&A deals, most of the acquisition targets were those that were involved in developing cancer drugs or gene therapies. Tripos International bought out Pharsight for $57M. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. An early-stage asset, codenamed BMN 307, is mired in trouble. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for $9.7 billion. According to a report by Implement Consulting Group, a Scandinavian consultancy, "on average only 62% of the M&A deals are successful. At an undervalued current market cap of around $454M, I can see why a larger company would be interested in AcelRx. Scott has long positions in 3 companies mentioned in this article. But there are some deals that Motley Fool contributors Brian Orelli and Keith Speights hope will happen. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. Want the latest recommendations from Zacks Investment Research? 3. Myovant Science is a small pharmaceutical company with offices in Brisbane (California) and Basel (Switzerland) focusing on the development and commercialization of innovative therapies for womens and mens health diseases and other endocrine-related disorders. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. Using these acquired allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis. Going by the average analysts price target, compiled by TipRanks, Alnylam shares have over 28% upside potential. The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. Example: +water -Europe In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. 10. Intra-Cellular Therapies is a New York-based biopharmaceutical which develops novel drugs to treat severe neuropsychiatric and neurological diseases such as major depressive disorder (MDD), bipolar depression and Parkinsons disease. That's right -- they think these 10 stocks are even better buys. Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Is this happening to you frequently? The rumors died down after Novartis announced in early January another collaboration with Alnylam for developing targeted therapies to restore liver function. Global Blood Therapeutics ( GBT) - $9B. 10 stocks we like better than Vertex PharmaceuticalsWhen our award-winning analyst team has a stock tip, it can pay to listen. product. Analysts, on average, predict over 75% upside for Crispr shares. And how much are they willing to spend? Subscribe to BioPharma Dive. Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. BioMarin remains on track to submit a Biologics License Application for Valoctocogene roxaparvovec to the FDA by the end of this year. Takeover rumors initially swirled around Clovis Oncology in 2013 when Rubraca, was in clinical trial stage. Alexion Pharma is no stranger to takeover rumors. On January 9, 2023, Biotech Acquisition Company (the "Company") received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), due to the . Cost basis and return based on previous market day close. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? Alnylams commercial RNAi therapeutic products are Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran), as well as Leqvio (inclisiran), with partner Novartis, which has obtained global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement. "Human natural killer cell" [Micrograph]. Sold Solvay Pharmaceuticals to Abbott Laboratories: Mr. King served as Senior Vice President of Commercial Operations at Solvay Pharmaceuticals. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Alnylam stock has a market capitalization of over $20 billion. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Leap Therapeutics, Inc. and Flame Biosciences, Inc. announced that the companies have entered into a definitive merger agreement pursuant to which Leap has acquired Flame and its assets, including FL-301, its clinical stage anti-Claudin18.2 monoclonal antibody, FL-302, its preclinical anti-Claudin18.2/CD137 bispecific monoclonal antibody, FL-501, its preclinical anti-GDF15 monoclonal antibody, and net cash of approximately $50 million as of December 31, 2022.
Bob Weir's Wife, Luckys Steakhouse Locations In Michigan, Murray Edwards Yacht,